3-ethylaniline
structure in first source
Networked: 3
relevant articles (0 outcomes,
0 trials/studies)
Bio-Agent Context: Research Results
Experts
| 1. | Skipper, Paul L:
2 articles
(05/2015 - 08/2006)
|
| 2. | Tannenbaum, Steven R:
2 articles
(05/2015 - 08/2006)
|
| 3. | Trudel, Laura J:
2 articles
(05/2015 - 08/2006)
|
| 4. | Wogan, Gerald N:
2 articles
(05/2015 - 08/2006)
|
| 5. | Chao, Ming-Wei:
1 article
(05/2015)
|
| 6. | Erkekoglu, Pınar:
1 article
(05/2015)
|
| 7. | Tseng, Chia-Yi:
1 article
(05/2015)
|
| 8. | Ye, Wenjie:
1 article
(05/2015)
|
| 9. | Egner, Patricia A:
1 article
(08/2006)
|
| 10. | Groopman, John D:
1 article
(08/2006)
|
Related Diseases
| 1. | Urinary Bladder Neoplasms (Bladder Cancer)
08/01/2006
- " Experimental evidence for carcinogenicity of monocylic aromatic amines is limited mostly to other organs, but a recent epidemiologic study of bladder cancer found that 2,6-dimethyl- (2,6-DMA), 3,5-dimethyl- (3,5-DMA), and 3-ethylaniline (3-EA) may play a significant role in the etiology of this disease in man. " 05/01/2015
- " Exposure to monocyclic aromatic alkylanilines (MAAs), namely 2,6-dimethylaniline (2,6-DMA), 3,5-dimethylaniline (3,5-DMA) and 3-ethylaniline (3-EA), was significantly and independently associated with bladder cancer incidence. "
|
| 2. | Neoplasms (Cancer)
|
|
Related Drugs and Biologics